[Mefloquine in the treatment of cutaneous leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis].
The aim of this study was to evaluate the efficacy of mefloquine in the treatment of skin leishmaniasis in patients infected with Leishmania (Viannia) braziliensis at an endemic region. Mefloquine is an oral drug effective against malaria with a prolonged half-life, less toxicity and easier administration than pentavalent antimonials. At Corte de Pedra in the Southern litoral of Bahia State, two randomized groups of ten patients with leishmaniasis were treated. The first group was treated with oral mefloquine, 250 mg per day in a single dose for six days and repeated three weeks later. The second group received meglumine antimoniate (Glucantime), 20 mg/kg daily administered intravenously for 20 days. Only one patient in the group treated with mefloquine showed evidence of clinical success. During treatment, one patient with four lesions developed a new lesion. The other three patients with clinical leismaniasis did not show evidence of clinical success after nine weeks of treatment. The group treated with Glucantime showed evident clinical improvement of the skin lesions.
Laguna-Torres
V A
VA
Núcleo de Medicina Tropical e Nutrição da Universidade de Brasília, DF. alaguna@oge.sld.pe
Silva
C A
CA
Correia
D
D
Carvalho
E M
EM
Magalhães
A V
AV
Macêdo
V de O
Vde O
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D019353:Endemic Diseases; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000453:epidemiology*; D015767:Mefloquine / Q000627:therapeutic use*
D000962:Antimalarials; D015767:Mefloquine